Published in Clin Vaccine Immunol on May 23, 2012
Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin. J Virol (2015) 0.83
Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations. J Virol (2014) 0.79
Viral vector-based influenza vaccines. Hum Vaccin Immunother (2016) 0.79
Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge. PLoS One (2016) 0.75
A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A (2000) 12.16
Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med (2001) 8.60
A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) (1991) 7.08
Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol (2005) 6.81
Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol (2005) 6.23
Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science (1989) 4.84
Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol (2004) 4.36
Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol (1993) 4.19
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology (1997) 3.62
A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol (2003) 2.85
Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J Virol (1996) 2.01
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest (2010) 1.71
Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. AIDS Res Hum Retroviruses (2003) 1.68
Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine (2009) 1.65
Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology (2005) 1.63
An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol (2003) 1.56
Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J Virol (2000) 1.52
Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life (2002) 1.41
Stable alphavirus packaging cell lines for Sindbis virus and Semliki Forest virus-derived vectors. Proc Natl Acad Sci U S A (1999) 1.38
Influenza virus. Curr Protoc Immunol (2001) 1.35
Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol (2004) 1.27
Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol (2007) 1.24
Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J Virol (2003) 1.23
Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine (2007) 1.19
Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology (2000) 1.19
Modulation of disease, T cell responses, and measles virus clearance in monkeys vaccinated with H-encoding alphavirus replicon particles. Proc Natl Acad Sci U S A (2005) 1.16
Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch Virol (2005) 1.11
Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. Clin Vaccine Immunol (2007) 1.08
Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine (2010) 1.08
The complete nucleotide sequence of the JS strain of human parainfluenza virus type 3: comparison with the Wash/47885/57 prototype strain. Virus Res (1992) 1.08
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine (2011) 1.07
Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J Gen Virol (2001) 1.04
Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine (2007) 1.03
Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res Hum Retroviruses (2006) 1.01
Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles. J Virol (2005) 1.00
A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol (2010) 0.99
Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles. J Infect Dis (2001) 0.98
An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J Virol (2007) 0.95
Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. Vaccine (2010) 0.92
Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol (2002) 0.92
Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. AIDS Res Hum Retroviruses (2006) 0.90
Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase. Vaccine (2012) 0.90
Adenoviruses as vectors for delivering vaccines to mucosal surfaces. J Biotechnol (2000) 0.89
A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge. Vaccine (2006) 0.87
Src kinases are required for a balanced production of IL-12/IL-23 in human dendritic cells activated by Toll-like receptor agonists. PLoS One (2010) 0.86
Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in mice. PLoS One (2010) 0.83
Evaluation of neurovirulence and biodistribution of Venezuelan equine encephalitis replicon particles expressing herpes simplex virus type 2 glycoprotein D. Vaccine (2006) 0.81
Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. Scand J Immunol (2007) 0.80
Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines. Vaccine (2006) 0.76
Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc Natl Acad Sci U S A (2005) 14.59
The microbial pan-genome. Curr Opin Genet Dev (2005) 5.93
Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci U S A (2002) 5.28
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
Microbiology in the post-genomic era. Nat Rev Microbiol (2008) 4.88
A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A (2006) 4.45
Pili in gram-positive pathogens. Nat Rev Microbiol (2006) 4.21
Single-cell RNA-Seq profiling of human preimplantation embryos and embryonic stem cells. Nat Struct Mol Biol (2013) 4.04
Genome analysis reveals pili in Group B Streptococcus. Science (2005) 3.85
Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science (2005) 3.83
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med (2003) 3.83
NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med (2002) 3.26
c-Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs. Mol Microbiol (2002) 3.20
Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A (2007) 3.11
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis (2013) 2.95
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med (2011) 2.75
Structure and dynamics of the pan-genome of Streptococcus pneumoniae and closely related species. Genome Biol (2010) 2.60
Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A (2012) 2.59
Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med (2011) 2.59
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A (2009) 2.41
Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology (2008) 2.37
A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med (2005) 2.35
Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J (2011) 2.33
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A (2010) 2.30
SARS--beginning to understand a new virus. Nat Rev Microbiol (2003) 2.30
Reverse vaccinology: developing vaccines in the era of genomics. Immunity (2010) 2.25
Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med (2010) 2.21
Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A (2007) 2.20
Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc Natl Acad Sci U S A (2003) 2.17
Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol (2006) 2.16
Fur functions as an activator and as a repressor of putative virulence genes in Neisseria meningitidis. Mol Microbiol (2004) 2.08
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A (2011) 2.08
Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS (2008) 2.06
Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol (2005) 2.06
Influenza vaccine immunology. Immunol Rev (2011) 2.02
Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine (2006) 1.99
New adjuvants for human vaccines. Curr Opin Immunol (2010) 1.98
Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun (2002) 1.94
Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc Natl Acad Sci U S A (2011) 1.84
Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol (2002) 1.83
Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One (2009) 1.82
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A (2005) 1.76
Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A (2010) 1.75
Comparative genomics of Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen-specific genes. Microbiology (2006) 1.75
Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun (2006) 1.74
Vaccine manufacturing: challenges and solutions. Nat Biotechnol (2006) 1.73
Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis (2003) 1.73
A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells. J Bacteriol (2008) 1.72
The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine (2012) 1.71
The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun (2005) 1.68
Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol (2008) 1.68
Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol (2006) 1.66
Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A (2010) 1.66
Clonal success of piliated penicillin nonsusceptible pneumococci. Proc Natl Acad Sci U S A (2007) 1.64
Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol (2003) 1.59
Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine (2009) 1.58
Phylogeny of the SARS coronavirus. Science (2003) 1.56
An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol (2003) 1.56
The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins. J Infect Dis (2004) 1.55
Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol (2002) 1.54
Molecular mechanisms of complement evasion: learning from staphylococci and meningococci. Nat Rev Microbiol (2010) 1.52
Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related. J Infect Dis (2008) 1.49
Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med (2013) 1.47
Pneumococcal pili are composed of protofilaments exposing adhesive clusters of Rrg A. PLoS Pathog (2008) 1.45
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A (2011) 1.44
Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. PLoS Pathog (2011) 1.42
NadA diversity and carriage in Neisseria meningitidis. Infect Immun (2004) 1.40
Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine (2011) 1.40
The history of MF59(®) adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines (2013) 1.39
Italy must invest more in science and technology. Nature (2008) 1.38
In vitro analysis of protein-operator interactions of the NikR and fur metal-responsive regulators of coregulated genes in Helicobacter pylori. J Bacteriol (2005) 1.36
Seasonal influenza vaccine provides priming for A/H1N1 immunization. Sci Transl Med (2009) 1.32
Autoregulation of Helicobacter pylori Fur revealed by functional analysis of the iron-binding site. Mol Microbiol (2002) 1.32
Vaccinology in the genome era. J Clin Invest (2009) 1.31
Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine (2010) 1.30
Neisseria meningitidis NhhA is a multifunctional trimeric autotransporter adhesin. Mol Microbiol (2006) 1.30
Growth phase-dependent regulation of target gene promoters for binding of the essential orphan response regulator HP1043 of Helicobacter pylori. J Bacteriol (2002) 1.29
Molecular architecture of Streptococcus pneumoniae TIGR4 pili. EMBO J (2009) 1.29
Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates. Virology (2007) 1.28
NKT-cell help to B lymphocytes can occur independently of cognate interaction. Blood (2008) 1.28
Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc Natl Acad Sci U S A (2011) 1.27
Genome sequencing of disease and carriage isolates of nontypeable Haemophilus influenzae identifies discrete population structure. Proc Natl Acad Sci U S A (2014) 1.27
Synthesis and characterization of a native, oligomeric form of recombinant severe acute respiratory syndrome coronavirus spike glycoprotein. J Virol (2004) 1.27
Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J Virol (2005) 1.27